西罗莫司纳米结构脂质载体分散液的制备及其体外释放度考察  

Preparation and in vitro releasing of sirolimus-nanostructured lipid carriers dispension

作　　者：吴昊[1,2] 宋洪涛[2] 

机构地区：[1]福建医科大学福总临床医学院,福建福州350025 [2]南京军区福州总医院药学科,福建福州350025

出　　处：《药学实践杂志》2012年第3期189-193,共5页Journal of Pharmaceutical Practice

基　　金：福建省自然科学基金(2010J01218)

摘　　要：目的优化西罗莫司纳米结构脂质载体(sirolimus nanostructured lipid carriers,SRL-NLC)分散液的处方,并考察其体外释放度。方法采用星点设计-效应面法(central composite design-response surface methodology,CCD-RSM)优化SRL-NLC分散液的处方,并以粒径、分布系数、载药量和包封率作为评价指标,采用正相透析袋法考察SRL-NLC分散液在0.4%SDS(十二烷基硫酸钠)溶液中的释放度。结果经优化的SRL-NLC分散液平均粒径82.54 nm、分布系数0.207,Zeta电位-18.0mv、载药量1.829%和包封率91.3%,SRL-NLC分散液在0.4%SDS溶液中能持续释放120 h,累积释放量为60.1%。结论经优化的处方可行性和重现性均较好,SRL-NLC分散液在0.4%SDS溶液中累积释放度为60.1%。Objective To optimize the preparation and study in vitro releasing of SRL-NLC dispersion. Methods Central composite design-response surface methodology was used to optimize dispersion formulation,then in vitro releasing in 0.4% SDS（ sodium lauryl sulfate） solution was explored by normal phase dialysis bag method. Results The optimal dispersion had PS（particle size） ： 82.54nm,PI（ polydisperity index） ： 0. 207, Zeta potential： - 18.0 mv, DL （drug-loading） ： 1. 829% , and EE （ entrapment efficiency） ： 91.3% ; SRL-NLC dispersion had a characterization of 60.1% accumulated releasing in 0.4% SDS solution, Conclusion The optimal formulation had good feasibility and reproducibility, in vitro releasing curve showed SRL-NLC dispersion had a characterization of 60.1% accumulated releasing in 0.4% SDS solution.

关 键 词：纳米结构脂质载体 制备 表征 正相透析袋法 体外释放 

分 类 号：R927.1[医药卫生—药学]